Cardiff Oncology CRDF 深 滬
等待開盤 11-04 09:30:00 美东时间
0.8631
+0.019
+2.23%
華盛通- 最 高0.8899
- 今 開0.85
- 成交量 22.50万股
- 最 低 0.8407
- 昨 收 0.8443
- 總市值 6714.51万
- 52周最高 3.31
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 0.7566
- 委 比 -31.35%
- 總股本 7779.52万
- 歷史最高 977.76
- 量 比 0.68
- 振 幅 5.83%
- 歷史最低 0.701
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cardiff Oncology to Participate in the UBS Global Biopharma Conference
Cardiff Oncology announced its participation in the UBS Global Biopharma Conference on November 16-17, 2026. CEO Mani Mohindru, PhD, will host a Fireside Chat on November 16 at 2:40 PM GMT. Investors can register and access the live webcast via the company's website. Cardiff Oncology focuses on PLK1 inhibition for cancer treatments, with its lead asset, onvansertib, in Phase 2 trials for RAS-mutated mCRC. More information is available at https://...
11-03 12:00
Cardiff Oncology Names Interim CMO Amid Trial Progress
Cardiff Oncology ( ($CRDF) ) has shared an announcement. Cardiff Oncology expan...
10-28 04:58
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology appoints Leila Alland, MD, as interim Chief Medical Officer, replacing Roger Sidhu, MD. Dr. Alland brings extensive oncology drug development experience, having led programs at多家生物制药公司, including AstraZeneca, Bristol Myers Squibb, and Novartis. Her expertise will guide Cardiff's Phase 3 study for onvansertib, a PLK1 inhibitor targeting RAS-mutated cancers, as the company prepares to initiate its registrational Phase 3 trial in ea...
10-27 20:05
Cardiff Oncology Shareholders Approve Expanded Capital Structure
Cardiff Oncology ( ($CRDF) ) just unveiled an update. On October 22, 2026, Card...
10-23 05:04
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology announced that the FDA granted Orphan Drug Designation to onvansertib for treating chronic myelomonocytic leukemia (CMML). Onvansertib, a PLK1 inhibitor, showed promise in early trials, with 40% of patients experiencing clinical benefits. Orphan Drug Designation offers benefits like tax credits and market exclusivity, supporting the development of therapies for rare diseases. Onvansertib is also being tested in other cancers, inc...
10-21 20:05
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.
09-15 18:28
Cardiff Oncology Amends Onvansertib License, Resolves Litigation
Cardiff Oncology ( ($CRDF) ) has shared an announcement. On September 14, 2026,...
09-14 21:47
Cardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology announced that Dr. Mani Mohindru will participate in two upcoming conferences: the 8th Annual RAS-Targeted Drug Development Summit on September 8, discussing PLK1-targeted therapy for RAS mutant metastatic colorectal cancer, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, featuring a fireside chat. Slides and webcast access will be available on the company's website post-conference. Cardiff Oncol...
09-02 11:00
